Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. The Company pipeline is purposeful: it applyie scientific expertise and courages to bring clinically meaningful therapies to patients. The Company believes science and compassion must work together to transform lives.
Company profile
Ticker
HZNP
Exchange
Website
CEO
Timothy P Walbert
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Horizon Pharma plc, HORIZON PHARMA, INC.
SEC CIK
Corporate docs
Subsidiaries
Horizon Medicines LLC • Horizon Therapeutics U.S. Holding LLC • Horizon Properties Holding LLC • Horizon Therapeutics Brasil Ltda • Horizon Therapeutics Capital Limited • Horizon Therapeutics Finance Limited • Horizon Therapeutics Finance • Horizon Therapeutics France SAS • Horizon Therapeutics GmbH • Horizon Therapeutics Holdings Limited ...
IRS number
272179987
HZNP stock data
Latest filings (excl ownership)
8-K
Other Events
5 Jun 23
8-K
Other Events
18 May 23
10-Q
2023 Q1
Quarterly report
3 May 23
8-K
Horizon Therapeutics plc Reports First-Quarter 2023 Financial Results
3 May 23
8-K
Other Events
17 Apr 23
8-K
Other Events
10 Apr 23
10-K
2022 FY
Annual report
1 Mar 23
8-K
Horizon Therapeutics plc Reports Fourth-Quarter and Full-Year 2022 Financial Results
1 Mar 23
8-K
Submission of Matters to a Vote of Security Holders
24 Feb 23
DEFA14A
Additional proxy soliciting materials
17 Feb 23
Transcripts
HZNP
Earnings call transcript
2022 Q3
2 Nov 22
HZNP
Earnings call transcript
2022 Q2
3 Aug 22
HZNP
Earnings call transcript
2022 Q1
4 May 22
HZNP
Earnings call transcript
2021 Q4
1 Mar 22
HZNP
Earnings call transcript
2021 Q3
3 Nov 21
HZNP
Earnings call transcript
2021 Q2
4 Aug 21
HZNP
Earnings call transcript
2021 Q1
5 May 21
HZNP
Earnings call transcript
2020 Q4
24 Feb 21
HZNP
Earnings call transcript
2020 Q3
2 Nov 20
HZNP
Earnings call transcript
2020 Q3
2 Nov 20
Financial summary
| Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 2.31 bn | 2.31 bn | 2.31 bn | 2.31 bn | 2.31 bn | 2.31 bn |
| Cash burn (monthly) | 13.74 mm | (no burn) | (no burn) | (no burn) | (no burn) | (no burn) |
| Cash used (since last report) | 30.10 mm | n/a | n/a | n/a | n/a | n/a |
| Cash remaining | 2.28 bn | n/a | n/a | n/a | n/a | n/a |
| Runway (months of cash) | 166.1 | n/a | n/a | n/a | n/a | n/a |
Institutional ownership, Q1 2023
77.9% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 535 |
| Opened positions | 77 |
| Closed positions | 149 |
| Increased positions | 164 |
| Reduced positions | 211 |
| 13F shares | Current |
|---|---|
| Total value | 19.40 tn |
| Total shares | 178.21 mm |
| Total puts | 7.61 mm |
| Total calls | 1.87 mm |
| Total put/call ratio | 4.1 |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 21.55 mm | $2.35 tn |
| BLK Blackrock | 14.93 mm | $1.63 tn |
| Avoro Capital Advisors | 7.00 mm | $763.98 bn |
| Pentwater Capital Management | 6.10 mm | $665.75 bn |
| JPM JPMorgan Chase & Co. | 5.49 mm | $598.83 bn |
| Farallon Capital Management | 5.42 mm | $591.52 bn |
| STT State Street | 5.12 mm | $559.00 bn |
| Citadel Advisors | 3.98 mm | $434.16 bn |
| Renaissance Technologies | 3.37 mm | $367.88 bn |
| Soros Fund Management | 3.29 mm | $359.27 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 9 May 23 | Himawan Jeff | Ordinary Shares | Gift | Acquire G | Yes | No | 0 | 7,873 | 0.00 | 7,873 |
| 9 May 23 | Himawan Jeff | Ordinary Shares | Gift | Dispose G | No | No | 0 | 7,873 | 0.00 | 2,121 |
| 28 Apr 23 | Grey Michael G | Ordinary Shares | Option exercise | Acquire M | No | No | 0 | 3,913 | 0.00 | 19,361 |
| 28 Apr 23 | Grey Michael G | RSU Ordinary Shares | Option exercise | Dispose M | No | No | 0 | 3,913 | 0.00 | 0 |
| 28 Apr 23 | Himawan Jeff | Ordinary Shares | Payment of exercise | Dispose F | No | No | 111.16 | 1,879 | 208.87 k | 9,994 |
| 28 Apr 23 | Himawan Jeff | Ordinary Shares | Option exercise | Acquire M | No | No | 0 | 3,913 | 0.00 | 11,873 |
| 28 Apr 23 | Himawan Jeff | RSU Ordinary Shares | Option exercise | Dispose M | No | No | 0 | 3,913 | 0.00 | 0 |
| 28 Apr 23 | Daniel William F | Ordinary Shares | Payment of exercise | Dispose F | No | No | 111.16 | 1,879 | 208.87 k | 31,915 |
| 28 Apr 23 | Daniel William F | Ordinary Shares | Option exercise | Acquire M | No | No | 0 | 3,913 | 0.00 | 33,794 |
| 28 Apr 23 | Daniel William F | RSU Ordinary Shares | Option exercise | Dispose M | No | No | 0 | 3,913 | 0.00 | 0 |
News
Biomarker Analysis Publication Highlights Key Signals Of Disability Worsening Associated With Neuromyelitis Optica Spectrum Disorder Attacks, Illustrates Efficacy Of UPLIZNA
1 Jun 23
10 Health Care Stocks With Whale Alerts In Today's Session
18 May 23
FDA Signals Support For Pfizer's Maternal RSV Shot Ahead Of Adcomm, Pfizer Raises $31B In Debt To Fund Seagen Deal
17 May 23
Horizon Therapeutics Options Trader Betting On A Major Dip For Stock By January 2024
17 May 23
FTC Files Lawsuit To Stop Amgen Buying Horizon Therapeutics, Sending Shockwaves Through Biopharma M&A
16 May 23
Press releases
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
2 Jun 23
Presentations at the 2023 EULAR European Congress of Rheumatology Highlight New Results from Phase 2 Trial Evaluating Dazodalibep in Sjögren's Syndrome
31 May 23
New Analyses of the MIRROR Randomized Controlled Trial in Uncontrolled Gout Presented at the 2023 EULAR European Congress of Rheumatology
31 May 23
Horizon Therapeutics plc Responds to U.S. Federal Trade Commission (FTC) Action to Block Acquisition by Amgen
16 May 23
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
10 May 23